Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corp. operated as a commercial-stage biopharmaceutical company developing and commercializing vaccines, with recurring announcements centered on its marketed products, pipeline and corporate status. The company commercialized HEPLISAV-B® vaccine, a hepatitis B vaccine approved in the U.S., European Union and United Kingdom for adults, and CpG 1018® adjuvant, which is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines.
Recurring updates include HEPLISAV-B revenue and financial results, share repurchase authorizations, investor conference presentations, licensing and collaboration activity, and clinical disclosures for vaccine candidates such as Z-1018 for shingles. Coverage also includes governance changes, material agreements, shareholder voting matters, capital-structure disclosures and public-company status updates.
Valneva SE and Dynavax Technologies Corporation have formed a commercial partnership for the supply of Dynavax's CpG 1018 adjuvant to be used in Valneva's COVID-19 vaccine candidate, VLA2001. The UK government has agreed to purchase up to 190 million doses of VLA2001 over five years. Dynavax will supply the adjuvant necessary for 100 million doses in 2021, with an option for an additional 90 million doses by 2025. VLA2001 is expected to enter clinical studies by the end of 2020 and aims for regulatory approval in the second half of 2021.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on September 14, 2020, at 10:00 a.m. ET. The event will be accessible via a webcast on the company's website under the 'Events & Presentations' section. Dynavax is focused on developing novel vaccines, including its first commercial product, HEPLISAV-B®, launched in February 2018, aimed at preventing hepatitis B infections in adults.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced a $3.4 million grant from the Bill & Melinda Gates Foundation to scale up production of its CpG 1018 adjuvant, which supports COVID-19 vaccine development. This funding aims to increase manufacturing capacity to 750 million doses annually, potentially aiding global vaccine distribution. CEO Ryan Spencer emphasized the importance of adjuvants in enhancing vaccine effectiveness. CpG 1018 has a proven track record with the FDA-approved HEPLISAV-B hepatitis B vaccine.
Dynavax Technologies Corporation (DVAX) reported second quarter 2020 financial results, revealing net product revenue of $2.4 million, a decline from $8.3 million in Q2 2019, primarily due to a significant drop in adult hepatitis B vaccine utilization caused by the COVID-19 pandemic. Despite this setback, the company's prospects remain positive with ongoing collaborations to develop adjuvanted vaccines, including COVID-19. The net loss for the quarter was $51.6 million, or $0.53 per share, with a cash position of $200.7 million as of June 30, 2020.
Dynavax Technologies Corporation (Nasdaq: DVAX) will announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company, known for developing novel vaccines, launched HEPLISAV-B® in February 2018, and is advancing CpG 1018 as a vaccine adjuvant with partnerships focused on vaccines for COVID-19, pertussis, and universal influenza. Access to the webcast will be available on their website, with a replay for 30 days post-event.
Dynavax Technologies (Nasdaq: DVAX) announced the appointment of Julie Eastland and Brent MacGregor to its Board of Directors. Julie brings over 25 years of experience in financial roles within biotechnology, while Brent has 20 years in global strategy and commercial operations, particularly in vaccines. Both are expected to provide strategic insights to strengthen Dynavax's position in the vaccine market, building on their established products like HEPLISAV-B and CpG 1018.
Dynavax Technologies (NASDAQ: DVAX) has announced a collaboration with Mount Sinai to develop a universal influenza vaccine. Funded by NIAID's CIVICs program, this initiative aims to combine Dynavax's CpG 1018 adjuvant with Mount Sinai's chimeric hemagglutinin technology. Current flu vaccines have variable effectiveness (10-60%), and this collaboration seeks to create a vaccine that may provide broader and longer-lasting protection against all strains of influenza. The program is set to support an IND application for Phase I clinical trials.
Dynavax Technologies Corporation has partnered with Times Pharmacy and Hep Free Hawaii to provide HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine, to at-risk populations in Hawaii, particularly people with diabetes. The vaccine is essential as individuals with diabetes are at higher risk for hepatitis B and related liver cancer. Vaccination aims to combat the high liver cancer rates in Hawaii, where it's the second highest in the U.S. HEPLISAV-B requires only two doses within a month, offering greater efficacy than previous vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on June 25, 2020, at 10:50 a.m. E.T. Interested parties can access the presentation through the 'Events & Presentations' section on Dynavax's investor website. Dynavax is focused on developing and commercializing novel vaccines, including HEPLISAV-B®, a Hepatitis B vaccine. The company is also advancing its CpG 1018 adjuvant for COVID-19 and pertussis vaccines. For more details, visit www.dynavax.com.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced the completion of enrollment for a clinical trial evaluating HEPLISAV-B® in adults with end-stage renal disease (ESRD) undergoing hemodialysis, enrolling 119 patients. The company anticipates final immunogenicity data in Q4 2020. The study aims to assess a new 4-dose regimen of HEPLISAV-B, which could offer an important vaccination alternative in this high-risk population. However, safety and effectiveness of the vaccine have not yet been established in these patients.